Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver
disease. There has been important progress in the field in recent years and the complexity of …

Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

There are no approved diagnostic biomarkers for at-risk non-alcoholic steatohepatitis
(NASH), defined by the presence of NASH, high histological activity and fibrosis stage≥ 2 …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AIH,
autoimmune hepatitis; ALF, acute liver failure; ALT, alanine aminotransferase; AMA …

Background The burden of non-alcoholic fatty liver disease (NAFLD) is increasing globally,
and a major priority is to identify patients with non-alcoholic steatohepatitis (NASH) who are …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …

An increasing percentage of people have or are at risk to develop non-alcoholic fatty liver
disease (NAFLD) worldwide. NAFLD comprises different stadia going from isolated steatosis …

The current epidemic of non-alcoholic fatty liver disease (NAFLD) is reshaping the field of
hepatology all around the world. The widespread diffusion of metabolic risk factors such as …

Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is
the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is …